baofeng wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. baofeng wang | Cancer Cell Biology | Best Researcher Award

Prof. baofeng wang, Department of Radiation Therapy, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an 710004, China, China

Dr. Baofeng Wang is a Professor and Associate Chief Physician at The Second Affiliated Hospital of Xi’an Jiaotong University. He serves as Head of the Abdominal Oncology Group in the Department of Radiation Oncology and is a Master’s Supervisor. Renowned for his expertise in abdominal and liver cancers, Dr. Wang actively contributes to several professional organizations, including the Chinese Society for Radiation Oncology (CSRO). As a reviewer for top journals and a recipient of multiple prestigious research awards, his work integrates clinical excellence with cutting-edge research. He has led three national and provincial-level projects and has authored over 40 scientific articles, with more than 10 published in SCI-indexed journals. His recent work focuses on ferroptosis, immune regulation in cancer, and BNCT treatment planning, marking him as a leading figure in translational oncology research.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Academic and Clinical Leadership:

    • Professor, Associate Chief Physician, and Master’s Supervisor.

    • Head of the Abdominal Oncology Group at a leading national medical institution.

    • Actively leads and shapes treatment protocols in radiation oncology.

  2. Research Productivity and Impact:

    • Authored over 40 scientific publications, with more than 10 indexed in SCI journals.

    • Principal Investigator for 3 major funded research projects.

    • Co-investigator in 5 additional national and provincial projects.

    • Reviewer for high-impact international journals, ensuring scientific rigor in oncology research.

  3. Recognition and Awards:

    • Winner of two First Prizes for Scientific and Technological Progress in Higher Education Institutions.

    • Received a Second Prize from the Shaanxi Provincial Scientific and Technological Progress Awards.

  4. Professional Influence:

    • Holds multiple key positions in national and provincial medical societies, especially within the Chinese Society for Radiation Oncology (CSRO).

    • Active in bridging research, clinical practice, and public health education.

  5. Recent Research Focus:

    • Investigating mechanisms of radioresistance via ferroptosis and cholesterol metabolism.

    • Advancing boron neutron capture therapy (BNCT) planning and immunoregulatory pathways in breast cancer and hepatocellular carcinoma.

⚙️ Areas for Improvement:

  1. Global Collaboration:

    • While domestically influential, expanding international collaborations and partnerships could further elevate the research impact and visibility.

  2. Citation Index and Research Translation:

    • Despite a good number of publications, a higher citation count and more translational outcomes into clinical practice would strengthen the award candidacy further.

  3. Innovation Leadership:

    • Developing patents or pioneering novel therapeutic technologies would add to innovation metrics.

🎓 Education:

Dr. Baofeng Wang received rigorous academic training in the medical sciences, specializing in oncology and radiation therapy. After completing his undergraduate medical degree, he pursued postgraduate studies focused on radiation oncology and tumor biology. His advanced academic pursuits led to a comprehensive understanding of radiobiology, imaging-guided radiotherapy, and molecular oncology. He continuously updates his knowledge through professional development programs and has contributed to both educational and research domains by mentoring postgraduate students. His commitment to academic excellence is evident through his role as a Master’s Supervisor, guiding the next generation of clinical researchers. Dr. Wang’s educational background has equipped him with the skills necessary to integrate evidence-based medicine with innovative research, particularly in the fields of liver cancer and immuno-oncology.

🧪 Professional Experience:

With over 15 years of clinical and academic experience, Dr. Baofeng Wang is a leading figure in the field of radiation oncology. Currently a Professor and Associate Chief Physician, he heads the Abdominal Oncology Group at The Second Affiliated Hospital of Xi’an Jiaotong University. He has been instrumental in developing individualized radiotherapy protocols for complex tumors. His leadership roles in various national and provincial oncology organizations highlight his influence in shaping cancer treatment strategies. He has served as Principal Investigator for several research grants from the National Natural Science Foundation of China and provincial R&D bodies. Additionally, Dr. Wang plays an active role in academic peer review and science promotion in Shaanxi province. His blend of clinical acumen and research proficiency makes him a cornerstone in the advancement of radiotherapy techniques and translational oncology.

🔬 Research Focus:

Dr. Wang’s research focuses on the intersection of radiation oncology, tumor metabolism, and immunoregulation. He investigates how cellular mechanisms such as ferroptosis and cytokine modulation contribute to radioresistance and tumor progression. A major area of interest is the optimization of boron neutron capture therapy (BNCT) treatment planning, aiming to enhance therapeutic outcomes in abdominal cancers. His work also explores the role of tumor-infiltrating immune cells and how factors like interleukin-10 influence immune suppression and therapy response. By integrating molecular diagnostics with imaging-guided radiotherapy, Dr. Wang seeks to improve precision medicine strategies. His translational research aims to convert lab-based discoveries into clinically viable cancer treatments, particularly for liver, breast, and gastrointestinal cancers. Through collaborative and interdisciplinary research, Dr. Wang’s work continues to push boundaries in oncology innovation.

📚 Publications Top Notes:

  1. 🧬 Recent research progress of BNCT treatment planning system

  2. 🔗 SCARB1 links cholesterol metabolism-mediated ferroptosis inhibition to radioresistance in tumor cells

  3. 🎯 BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

  4. 🛡️ Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

📌 Conclusion:

Dr. Baofeng Wang exemplifies the qualities of an exceptional clinical researcher, balancing leadership, clinical service, and impactful research. His contributions to radiation oncology—particularly in abdominal and liver cancers—along with national-level recognition and funding, make him a highly suitable and competitive candidate for the Best Researcher Award. Continued expansion of his international footprint and translational outputs would position him even more prominently on the global stage.

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

  1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

  2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

  3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

  4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

  5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

  6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.

Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Dr. Zu-Chian Chiang , Fujian Normal University , China

Dr. Zu-Chian Chiang is a highly accomplished postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, specializing in cancer research and regenerative medicine. With extensive experience in antibody-drug conjugates (ADCs), peptide synthesis, and tissue engineering, his work focuses on the development of targeted therapies and innovative biomaterials for medical applications. Dr. Chiang’s expertise includes both academic research and real-world clinical applications, and he has contributed to numerous peer-reviewed publications and conference presentations. Over the years, his research has received recognition from prestigious institutions such as the National Taiwan University and Academia Sinica. He also plays an active role in academic societies, providing his expertise as a peer reviewer for various scientific journals and as a key member of multiple international organizations. Dr. Chiang continues to make significant strides in biomedical engineering and cancer therapy.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Education and Experience:

    • Dr. Chiang has a robust academic background, with a Ph.D. in Materials and Chemical Engineering and an M.S. in Chemistry, both from reputable institutions in Taiwan. His postdoctoral experience spans multiple prestigious institutions, such as Academia Sinica and National Taiwan University Hospital, and his ongoing postdoc at the Biomedical Research Center of Southern China showcases his continued dedication to scientific progress.

  2. Research Excellence:

    • Dr. Chiang has made significant contributions to the field of cancer research, particularly in antibody-drug conjugates (ADCs), functional peptides for cancer research, and the development of specific aptamers as targeted therapies for cancer.

    • He has authored numerous high-quality peer-reviewed publications (with recent impactful papers), contributing to advancing understanding in immunotherapy, ADCs, and cancer therapeutics. His research has garnered attention in journals like Frontiers in Oncology and PLOS ONE.

  3. Awards and Recognition:

    • Dr. Chiang’s receipt of multiple prestigious awards, such as the 3rd Biotech Elite Training Reserve Program award, highlights his excellence in both academic and professional research. His achievements have earned recognition from both Taiwanese and Chinese scientific communities.

  4. Active Contribution to the Scientific Community:

    • Serving as a peer reviewer for the International Journal of Biological Macromolecules, as well as being involved in numerous scientific societies, demonstrates his commitment to advancing the field and his active engagement with the wider scientific community.

  5. Research Support and Funding:

    • Dr. Chiang has successfully secured research funding from prominent sources, such as the Department of Human Resources and Social Security, Fujian Province, showcasing his ability to lead and manage significant research projects. His ongoing research projects reflect a focus on cancer therapies and therapeutic advancements, further cementing his relevance in the field.

Areas for Improvement:

  1. Public Engagement and Outreach:

    • While Dr. Chiang has impressive research achievements, further expanding his presence in broader public engagement, such as science communication, could help make his findings accessible to a larger audience, especially in cancer therapy and regenerative medicine.

  2. Collaboration and Networking:

    • Dr. Chiang’s research has been highly productive, but future collaboration with other interdisciplinary teams could increase the breadth of his work and facilitate the development of novel, cross-disciplinary solutions.

  3. Increasing Citation Impact:

    • Although Dr. Chiang has 91 citations, his h-index of 5 suggests there may be room to increase the visibility and citation impact of his work. Strategic publishing in highly-cited journals or working with larger collaborative projects could elevate this metric.

  4. Mentorship and Training:

    • While his extensive postdoctoral training is impressive, Dr. Chiang’s experience in mentorship or leading research teams could be enhanced further. Serving as a mentor for students and junior researchers could help strengthen his leadership in the scientific community.

Education:

Dr. Zu-Chian Chiang earned his Ph.D. in Materials and Chemical Engineering from National United University, Taiwan (2008-2014), where he specialized in biomedical engineering under the mentorship of Professor An-Chong Chao and Dr. Guo-Chung Dong. Prior to that, he completed his M.S. in Chemistry from Tunghai University, Taiwan (2005-2007), under the guidance of Professor Feng-Di Lung. His doctoral research focused on creating innovative materials for biomedical applications, such as scaffolds for tissue engineering. Throughout his academic career, Dr. Chiang was awarded scholarships and fellowships recognizing his excellence in research, such as the First Outstanding Doctoral Scholarship at National United University and the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan. His academic foundation laid the groundwork for his cutting-edge contributions to cancer research, drug delivery, and regenerative medicine, ensuring his continued impact in the field.

Experience:

Dr. Zu-Chian Chiang has accumulated a wealth of research experience, serving as a postdoctoral fellow at various prestigious institutions. Since September 2019, he has been working at the Biomedical Research Center of Southern China, Fujian Normal University, focusing on cancer therapies and advanced drug delivery systems. Prior to this, he held postdoctoral positions at the Institute of Biological Chemistry, Academia Sinica (2016-2019), and National Taiwan University Hospital’s Clinical Trial Center (2015-2016), where he worked on pioneering biotechnological projects, including the Taiwan Protein Project. Dr. Chiang’s expertise extends to developing antibody-drug conjugates (ADCs), functional peptides, and biomaterials for regenerative medicine. His involvement in various research groups has strengthened his interdisciplinary knowledge in both molecular and clinical aspects of cancer therapy. Dr. Chiang also gained valuable teaching experience while completing his degrees, serving as a teaching assistant in organic chemistry and chemical engineering courses throughout his academic career.

Awards and Honors:

Dr. Zu-Chian Chiang has received numerous prestigious awards throughout his career, reflecting his significant contributions to the field of biomedical research. Notable honors include the “Science and Technology Commissioner” title in Quanzhou, Fujian Province (2020), and the “Miaoli Southeastern Xindong Satellite Rotary Club Chairman Award” (2017). In 2016, he was honored as an awardee of the “3rd Biotech Elite Training Reserve Program” by National Taiwan University and Taiwan’s Ministry of Science and Technology. His academic achievements were further recognized with the Chung Hwa Rotary Annual Doctoral Program Award (2012), and he received the First Outstanding Doctoral Scholarship at National United University (2010). Additionally, Dr. Chiang was awarded the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan (2007). These accolades reflect his outstanding dedication to scientific research, education, and professional development in the fields of cancer therapy and regenerative medicine.

Research Focus:

Dr. Zu-Chian Chiang’s primary research interests lie in the development of functional peptides for cancer therapy and tissue engineering, as well as the design of advanced biomolecular materials for regenerative medicine. His work focuses on antibody-drug conjugates (ADCs), targeting specific cancer cells for more effective therapies. One of his key research areas is developing specific aptamers as blockers, agonists, or antagonists for cancer treatment, aiming to enhance therapeutic outcomes. He is also dedicated to the synthesis of peptides that can aid in the regeneration of bone tissue and the creation of biomaterials that combine bioactive molecules for regenerative medicine. Through his research, Dr. Chiang aims to improve cancer treatments by targeting tumors more precisely, reduce side effects, and contribute to breakthroughs in drug delivery. His work also explores innovative methods of using biomaterials for enhancing regenerative medicine, thus bridging the gap between basic science and clinical application.

Publications Top Notes:

  1. “Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects” 🧬💉

  2. “Strengthening effect of thalidomide combined with anti-PD1 antibody on enhancing immunity for lung cancer therapy” 🫁💪

  3. “Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo” 🫀⚛️

  4. “Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells” 🧪🧫

  5. “Preparation and characterization of dexamethasone-immobilized chitosan scaffold” 💊🧵

  6. “Characterization of the morphology and hydrophilicity of chitosan/caffeic acid hybrid scaffolds” 🧫🌿

  7. “Preparation and characterization of caffeic acid grafted chitosan/CPTMS hybrid scaffolds” 🍄🔬

Conclusion:

Dr. Zu-Chian Chiang is a highly qualified and accomplished researcher, with a strong track record in cancer research and therapeutic innovation. His work in developing antibody-drug conjugates, functional peptides, and aptamers demonstrates great promise in transforming cancer therapy. His academic credentials, publications, awards, and research funding solidify his standing as a top candidate for the Best Researcher Award. Further expansion into public engagement, interdisciplinary collaborations, and mentorship could further enhance his contributions to the field and his overall impact. Therefore, Dr. Chiang is certainly a strong contender for the award, with potential for even greater influence moving forward.

Rezaul Karim | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Mr. Rezaul Karim | Cancer Cell Biology | Best Researcher Award

Mr. Rezaul Karim , Department of Mathematics, Mawlana Bashani science and Technology University , Bangladesh

Rezaul Karim is an Assistant Professor in the Department of Mathematics at Mawlana Bhashani Science and Technology University, Tangail, Bangladesh. He holds an MS and BSc in Mathematics from the same institution. Rezaul’s academic career is marked by his passion for research and teaching in the field of applied mathematics, particularly focusing on mathematical modeling, nonlinear oscillation, and numerical analysis. With numerous publications in reputable journals and a series of collaborative projects, he has contributed significantly to the academic community. He has also served as a guest lecturer at various institutions, demonstrating his dedication to advancing mathematical education. His work has earned him recognition in the field, making him a promising candidate for awards and research grants.

Publication Profile:

Orcid

Strengths for the Award:

  1. Academic and Research Excellence: Rezaul Karim has an impressive academic and professional background, with a career in teaching at the university level. As an Assistant Professor at Mawlana Bhashani Science and Technology University, he has made notable contributions to the field of mathematics, particularly in nonlinear differential systems, mathematical modeling, and numerical analysis. His research has been published in reputable international journals, reflecting the impact and quality of his work.

  2. Diverse Research Interests: Rezaul Karim’s research interests span a broad range of topics, including nonlinear oscillations, mathematical modeling, population dynamics, and numerical analysis. He has worked extensively on approximation solutions to nonlinear differential equations and has contributed to the field through numerous publications, showing a robust and diverse research output.

  3. Extensive Publication Record: With over 19 publications in peer-reviewed journals, Rezaul Karim has consistently demonstrated his ability to contribute to the academic community. His work addresses critical problems in applied mathematics and theoretical modeling, particularly in relation to population projections and nonlinear systems. He has also co-authored papers with prominent researchers in the field, adding to his credibility and influence in the mathematical research community.

  4. Mentorship and Collaboration: Karim’s role as a faculty member and his collaboration with other researchers demonstrate his commitment to mentorship and collaboration. He has worked with various colleagues, showing his ability to contribute to multidisciplinary projects and guide emerging researchers in the field.

  5. Awards and Recognitions: He has received recognition for his achievements, including foundation training for university teachers and scholarships during his academic journey. His contributions to inter-university quiz competitions and success in various faculty-based scholarships further highlight his passion and competence.

Areas for Improvement:

  1. Expanding Research Impact: While Rezaul Karim has a strong publication record, his research could benefit from being more widely recognized in interdisciplinary fields. Increasing the visibility of his work in broader scientific communities or in applied industries could enhance his profile as a researcher.

  2. Engagement in International Conferences and Symposiums: Although Karim has published widely, further engagement in international conferences, symposiums, and research workshops could allow him to exchange ideas and stay updated with the latest trends in his research areas. This would also help in broadening his professional network.

  3. Collaborations in Industry-Based Research: A possible avenue for improvement would be to engage in industry-based research that applies mathematical models and numerical analysis to real-world problems, such as in engineering, healthcare, or technology. This could help increase the practical impact of his work.

  4. Developing Interdisciplinary Projects: While Karim’s work is deeply rooted in mathematics, expanding into interdisciplinary research projects, such as integrating mathematical modeling with other domains like biology, economics, or environmental science, could enrich his research profile and broaden its scope.

Education:

Rezaul Karim pursued his educational journey at Mawlana Bhashani Science and Technology University. He completed his MS in Mathematics in 2015, earning a CGPA of 3.78 out of 4.0. Prior to this, he obtained a BSc (Hons) in Mathematics in 2014, with a CGPA of 3.65 out of 4.0. His strong academic background was built upon solid foundational education, which began in high school, where he achieved excellent results in science subjects. His commitment to excellence in mathematics has been evident throughout his academic career, culminating in several research-based projects that have contributed to the advancement of applied mathematics in real-world contexts.

Experience:

Rezaul Karim has been serving as an Assistant Professor in the Department of Mathematics at Mawlana Bhashani Science and Technology University since February 2020. Prior to this role, he held positions as a guest lecturer at Jamalpur Bangamata Sheikh Fazilatunessa Mujib Science and Technology University from January to July 2023 and as a lecturer in the CSE Department at the College of Business Science and Technology (CBST), Mymensingh, from 2018 to 2020. Rezaul has also taught at various university coaching centers, where he mentored students for university admission exams. His professional experience extends beyond teaching, having engaged in multiple research collaborations and projects. He brings a wealth of knowledge and expertise in mathematics, with a focus on problem-solving and theoretical analysis in nonlinear differential systems and mathematical modeling.

Awards and Honors:

Rezaul Karim has received multiple awards and honors for his academic achievements. Notably, he secured the 5th position in scholarships within the science faculty during his third and fourth semesters. He has also been recognized as a runner-up in the inter-university quiz competition. His teaching prowess was further enhanced by attending Foundation Training for University Teachers (GTI), which solidified his role as an effective educator. These awards demonstrate his dedication to both his studies and teaching career. Karim’s scholarly contributions have earned him recognition in the field of mathematics, especially in research and the publication of several influential papers in esteemed journals. These honors and accolades reflect his commitment to academic excellence and teaching.

Research Focus:

Rezaul Karim’s research focus lies in mathematical modeling, nonlinear oscillation, and numerical analysis. He explores approximate solutions for nonlinear differential equations, particularly in systems with varying parameters. His research interests also extend to investigating the stability and behavior of population models and differential systems. Rezaul has published numerous articles that contribute to the mathematical modeling of real-world phenomena, such as population growth projections using Malthusian and logistic models. His work in nonlinear oscillations is significant, as he focuses on damped and forced oscillatory motions in complex systems. In addition, his research involves analyzing the accuracy of numerical methods for solving differential equations. His work seeks to bridge the gap between theoretical mathematics and practical applications, particularly in environmental and biological modeling. This ongoing commitment to research further exemplifies his drive to advance the field of applied mathematics.

Publications Top Notes:

  1. “Approximate solution of nonlinear differential system with time variation” 📝 (Journal of Bangladesh Academy of Sciences, 2021)
  2. “Accuracy Analysis on Solution of Initial Value Problems of Ordinary Differential Equations” 📝 (Int. Ann. Sci., 2021)
  3. “Approximate Solution of Damped Forced and Damped Oscillatory Motion” 📝 (Progress in Nonlinear Dynamics and Chaos, 2021)
  4. “Stability of Two and Three Species Population Models” 📝 (Advances in Mathematical Sciences, 2020)
  5. “A Comparative Exploration on Different Numerical Methods for Solving Ordinary Differential Equations” 📝 (J. Mechanics of Continua, 2020)
  6. “Future Population Projection of Bangladesh using Malthusian and Other Models” 📝 (Int J Stat Appl Math, 2020)
  7. “KB Method for Obtaining Approximate Solution of Slowly Varying Amplitude and Phase” 📝 (Int J Stat Appl Math, 2020)
  8. “De-Speckling of SAR Images with Fuzzy Filters” 📝 (Journal of Computer and Communications, 2022)
  9. “Soliton Solutions to Nonlinear Wave Equations” 📝 (J. Umm Al-Qura University for Applied Sciences, 2024)
  10. “Prediction of Family Planning and Health Effects on Bangladesh Using Age Structure Model” 📝 (J. Mechanics of Continua, 2024)

Conclusion:

Rezaul Karim is a highly deserving candidate for the Best Researcher Award due to his exceptional academic contributions, diverse research interests, and significant publication record. His work in mathematical modeling, nonlinear differential systems, and numerical methods has made a substantial impact on both theoretical and applied mathematics. Karim’s dedication to research, coupled with his teaching and mentoring role, positions him as an influential figure in the field.

Haijiao Zhang | Cellular Stress Response | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Haijiao Zhang | Cellular Stress Response | Best Researcher Award

Assist. Prof. Dr. Haijiao Zhang , Oregon Health & Science University , United States

Haijiao Zhang is an Assistant Professor at Oregon Health & Science University, specializing in oncological sciences. With a background in medicine and extensive research experience, Zhang has contributed significantly to leukemia studies and cancer therapies. After completing his undergraduate studies at Jilin University, he pursued advanced degrees at Hannover Medical School and the Knight Cancer Institute. Zhang’s work focuses on uncovering genetic mechanisms and drug resistance in blood cancers, particularly acute myeloid leukemia (AML) and chronic neutrophilic leukemia (CNL). His research has led to several groundbreaking discoveries and publications in prestigious journals, advancing our understanding of cancer genomics and treatment resistance. As a postdoctoral fellow, Zhang discovered new mechanisms linked to CFS3R mutations, contributing to novel therapeutic strategies. His dedication to precision medicine continues to shape the future of cancer research.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Academic and Professional Excellence: Haijiao Zhang has demonstrated significant expertise in oncological sciences, specifically focusing on cancer genomics, tumor biology, and drug resistance mechanisms. Their progression from a postdoctoral fellow to an assistant professor at Oregon Health & Science University (OHSU) highlights their leadership and dedication to advancing cancer research.

  2. Groundbreaking Research Contributions: Dr. Zhang has been pivotal in uncovering molecular mechanisms behind drug resistance in cancers such as acute myeloid leukemia (AML) and chronic neutrophilic leukemia (CNL). For instance, their discovery of diverse non-FLT3 molecular mechanisms of resistance to crenolanib in AML is a valuable contribution to understanding treatment resistance.

  3. Publication Record: Dr. Zhang has an impressive record of high-impact publications in peer-reviewed journals, including Blood, Cancer Cell, Signal Transduction and Targeted Therapy, and Nature Cancer. These publications often tackle critical challenges in cancer treatment, including mechanisms of drug resistance and potential therapeutic targets, which are directly relevant to the clinical treatment of leukemia and other cancers.

  4. Innovative Scholarship: Their research on the genomic landscape of neutrophilic leukemias and biomarkers predicting venetoclax efficacy showcases a forward-thinking approach to precision medicine. This positions Dr. Zhang as a leading researcher in biomarker identification and targeted cancer therapies.

  5. Grants and Funding: Dr. Zhang’s ability to secure significant funding, such as the R01CA297224-01 grant, which explores mitochondrial dysfunction in hematological disorders, demonstrates recognition of their research’s potential impact on clinical outcomes in cancer treatment.

  6. Recognition in the Scientific Community: Their involvement in major conferences, such as the Beat AML symposium, and their collaborations with international experts further solidify their reputation in the field of oncological research.

Areas for Improvement:

  1. Broader International Collaboration: While Dr. Zhang has already made notable contributions within the U.S. and Europe, expanding collaborations with researchers in Asia and other parts of the world could enhance the global impact of their work and open up new avenues for interdisciplinary research.

  2. Involvement in Clinical Trials: Although Dr. Zhang’s work is highly relevant to clinical outcomes, increasing involvement in clinical trial design or translation of findings into clinical settings could help bridge the gap between basic science and patient care. This would also make their research directly applicable to the next generation of therapeutic interventions.

  3. Public Outreach and Education: Dr. Zhang could consider increasing their involvement in public outreach, particularly in educating patients and communities about the implications of their research. Such initiatives could contribute to greater awareness and understanding of the role of genomics in cancer treatment.

Education:

Haijiao Zhang’s academic journey began with a Bachelor of Medicine (B. Med) from Jilin University (2005-2010). He then pursued a Master’s in Medicine (M. Med) at the First Hospital of Jilin University (2010-2012), before moving to Hannover Medical School in Germany, where he earned his Doctor of Medicine (M.D.) degree (2012-2015). Following his M.D., Zhang joined the prestigious Knight Cancer Institute at Oregon Health & Science University for postgraduate research (2015-2020). His work at the Knight Cancer Institute has been instrumental in his academic and professional growth, particularly in oncology research, where he focused on genetic mutations and drug resistance mechanisms in hematologic malignancies. With a strong foundation in clinical and experimental oncology, Zhang combines his medical training with cutting-edge research to advance cancer treatment strategies.

Experience:

Haijiao Zhang is currently an Assistant Professor at Oregon Health & Science University in the Division of Oncological Sciences, a position he has held since July 2021. Prior to his faculty appointment, he was a Postdoctoral Fellow at the same institution (2015–2020), where he worked under the mentorship of prominent researchers in cancer genomics. In the early years of his postdoc, Zhang identified novel mechanisms related to chronic neutrophilic leukemia (CNL) and CFS3R mutations. He has also collaborated on high-impact research regarding cancer drug resistance, focusing on therapeutic strategies for AML. His research interests primarily involve chromosome deletions, oncogenes, tumor suppressor genes, and the molecular mechanisms underlying cancer drug resistance. Zhang’s work has been widely published and is considered foundational in the field. His efforts aim to personalize cancer therapies by understanding genetic drivers of malignancies, ultimately improving patient outcomes.

Awards and Honors:

Haijiao Zhang has received numerous honors and awards for his academic and research achievements. Notably, in 2014, he earned the Best Abstract Award at the 21st Jahrestagung der Deutschen Gesellschaft für Immungenetik. In the same year, he received a Travel Grant for the 47th Annual Meeting of the German Society for Transfusion Medicine and Immunohematology. Zhang’s early academic accomplishments were recognized with a range of awards, including a Travel Grant in 2012 and accolades in 2009 and 2008. His commitment to advancing cancer research has not only led to multiple successful grant applications but has also made him a sought-after speaker at major scientific conferences. His contributions have been instrumental in improving the understanding of drug resistance in leukemia, earning him recognition from peers and institutions alike. Zhang’s expertise continues to shape the field of hematology and oncology, inspiring future breakthroughs in cancer treatment.

Research Focus:

Haijiao Zhang’s research primarily focuses on understanding the genetic and molecular mechanisms behind hematologic cancers, particularly leukemia. His work investigates chromosome abnormalities, such as copy number deletions, and their role in cancer progression. He has contributed significantly to understanding drug resistance mechanisms, particularly in acute myeloid leukemia (AML) and chronic neutrophilic leukemia (CNL). Zhang is particularly interested in targeting mitochondrial dysfunction as a potential therapeutic strategy for hematological disorders, as seen in his work on -7del(7q) mutations. His research aims to identify new biomarkers for cancer prognosis and treatment responses. By analyzing drug resistance and genomic landscapes, Zhang strives to personalize cancer treatments and improve patient outcomes. His innovative approach combines molecular genetics, drug discovery, and cancer biology, pushing the boundaries of precision medicine. Zhang’s ongoing research promises to offer novel therapeutic targets and strategies for overcoming current treatment limitations in blood cancers.

Publications Top Notes:

  1. A CEBPB/IL-1β/TNF-α Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia 🩸
  2. Upregulation of HOXA3 by Isoform-Specific Wilms Tumor 1 Drives Chemotherapy Resistance in Acute Myeloid Leukemia 💉
  3. CDK12/13 Dual Inhibitors Are Potential Therapeutics for Acute Myeloid Leukemia 🧬
  4. Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia 🔬
  5. Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia 💊
  6. Biomarkers Predicting Venetoclax Efficacy and Venetoclax Combination Strategies 🔬
  7. Genomic Landscape of Neutrophilic Leukemias of Ambiguous Diagnosis 🧬
  8. Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms 💉
  9. Two Myeloid Leukemia Cases with Rare FLT3 Fusions 🧬
  10. Functional Genomic Landscape of Acute Myeloid Leukemia 🔬

Conclusion:

Dr. Haijiao Zhang is highly deserving of the Best Researcher Award due to their groundbreaking contributions to cancer research, particularly in understanding the molecular mechanisms of drug resistance in leukemia. Their ability to conduct impactful research, secure prestigious funding, and consistently publish in top-tier journals underscores their commitment to advancing the field of oncological sciences. While there is room for growth in clinical trial involvement and international collaboration, Dr. Zhang’s ongoing research promises to shape future cancer therapies and improve patient outcomes.

 

 

 

Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Ana Figueiras , Faculty of Pharmacy/University of Coimbra , Portugal

Ana Rita Ramalho Figueiras is an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, Portugal, and a researcher at REQUIMTE/LAQV, focusing on Pharmaceutical Technology. She earned her PhD in Pharmaceutics from the University of Coimbra in 2009, specializing in drug delivery systems, particularly for cancer treatments. Throughout her career, Ana has worked on advancing the development of block copolymers and micellar systems for targeted drug delivery. With a strong academic background and international exposure, she has contributed significantly to the fields of pharmaceutics, drug formulation, and pharmaceutical sciences. Ana’s work has been recognized through various publications in top journals, and she is deeply involved in mentoring post-doctoral researchers. Her expertise and leadership in pharmaceutical research continue to influence the development of innovative therapies in the pharmaceutical field.

Publication Profile: 

Orcid

Strengths for the Award:

Ana Rita Ramalho Figueiras is a highly accomplished researcher in pharmaceutical sciences, with extensive contributions to drug delivery systems, particularly focusing on micellar systems and polymeric micelles for cancer therapy. Her interdisciplinary work bridges pharmaceutics, chemistry, and biomedicine, showcasing her ability to innovate within drug delivery mechanisms for complex diseases. As an Assistant Professor at the University of Coimbra and an integrated member of the REQUIMTE/LAQV research group, she brings a wealth of academic and research leadership to her field.

Her innovative contributions have been recognized with various academic awards, including distinctions for oral communications and publications. Additionally, she has made substantial contributions to numerous collaborative research projects, focusing on the development of novel therapeutic strategies and drug delivery systems that target poorly soluble drugs, cancer therapies, and chronic diseases like Alzheimer’s.

Areas for Improvement:

While Figueiras is a leading figure in the scientific community, expanding her outreach to a broader range of international research collaborations could further amplify her impact. Although her work on drug delivery systems has significant potential for clinical applications, there could be further focus on translating her findings from bench to bedside by collaborating with clinical researchers for clinical trials and regulatory studies. A stronger emphasis on commercialization of her research could also be beneficial for broader societal impact.

Education:

Ana Rita Ramalho Figueiras pursued her academic journey in the field of Pharmaceutical Sciences, beginning at the University of Coimbra in Portugal. She graduated with a degree in Pharmaceutical Sciences in 2002, followed by a PhD in Pharmaceutics at the same university in 2009. Her doctoral research was focused on enhancing drug solubility and permeability, with a specific focus on cyclodextrins and mucoadhesive polymers for buccal drug delivery. During her PhD, she gained international exposure by collaborating with the University of Santiago de Compostela, Spain, and the University of Innsbruck, Austria. She is also registered as a member of the Ordem dos Farmacêuticos in Portugal since 2003. Ana’s educational foundation, combined with her interdisciplinary collaborations, has provided her with a robust understanding of pharmaceutical sciences and technologies, forming the cornerstone of her impactful career in academia and research.

Experience:

Ana Rita Ramalho Figueiras has been an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, since September 2014, where she is an integrated Ph.D. member in the Pharmaceutical Technology group of REQUIMTE/LAQV. Prior to this, she was an Invited Assistant Professor from 2013 to 2014, working closely with the Center of Neuroscience and Cell Biology (CNC/UC) and contributing as a collaborator in the Health Sciences Research Centre (CICS/UBI). Her academic roles involve teaching, mentoring students and postdoctoral fellows, and leading research projects on advanced drug delivery systems. She has also been involved in supervising several postdoctoral researchers, focusing on developing and characterizing polymeric micellar systems and controlled delivery systems for drugs like pilocarpine. Throughout her career, Ana has participated in various scientific projects, bringing valuable insights into the design of innovative drug delivery platforms with applications in cancer therapy and other medical conditions.

Awards and Honors:

Ana Rita Ramalho Figueiras has received several accolades for her research excellence and contributions to the field of Pharmaceutical Sciences. In 2004, she was awarded a prestigious PhD fellowship by Fundação para a Ciência e Tecnologia (FCT), which enabled her to pursue her doctoral studies. In 2011, she received the Best Short Communication Award at the VI Annual CICS Symposium for her work on new therapeutic strategies for siRNA delivery. In 2012, she was honored with the Best Oral Communication Award for her research on Poloxamine-α-cyclodextrin supramolecular gels promoting osteogenic differentiation of mesenchymal stem cells. These awards underscore her commitment to scientific advancement, as she continues to lead innovative research in drug delivery systems, nanomedicine, and cancer therapy. Ana’s dedication to advancing pharmaceutics has also led her to mentor future generations of researchers, further solidifying her reputation as a leading academic in her field.

Research Focus:

Ana Rita Ramalho Figueiras focuses her research on developing advanced drug delivery systems, specifically in the context of cancer therapies. Her primary research interest lies in utilizing block copolymers and micellar systems for targeted and controlled drug release. This includes the formulation of poorly water-soluble drugs, improving their bioavailability, and creating novel pharmaceutical formulations for effective treatment. Ana is particularly interested in the development of polymeric micelles for the delivery of therapeutic agents, including drugs and genes, to treat various diseases, with a strong emphasis on oncology. Additionally, her research investigates the use of mucoadhesive polymers for drug delivery to mucosal surfaces. With a commitment to improving drug efficacy and reducing side effects, her work aims to enhance patient outcomes through innovative drug formulations. Ana is also involved in several projects that explore natural compounds and their potential for pharmaceutical applications, further contributing to advancements in the drug delivery and pharmaceutical fields.

Publications Top Notes:

  1. “Unraveling Rosmarinic Acid Anticancer Mechanisms in Oral Cancer Malignant Transformation” 🎗️🦷
  2. “Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts” 💄⚖️
  3. “The Many Faces of Cyclodextrins within Self-Assembling Polymer Nanovehicles: From Inclusion Complexes to Valuable Structural and Functional Elements” 🔬🧪
  4. “Development and Characterization of Curcumin-Loaded TPGS/F127/P123 Polymeric Micelles as a Potential Therapy for Colorectal Cancer” 🍂⚕️
  5. “Pulmonary Delivery of Bacterial Lysates Mediated by Locust Bean Gum Microparticles” 🌬️🦠
  6. “Non-Toxic Mucoadhesive Locust Bean Gum Microparticles for Delivery of Bacterial Lysates to Prevent Respiratory Diseases” 🌱🫁
  7. “Polymersomes as the Next Attractive Generation of Drug Delivery Systems: Definition, Synthesis and Applications” 🧫💊
  8. “Nanotheranostics: The Afterglow for Cancer Immunotherapy” 💡💉
  9. “Acanthus Mollis Formulations for Transdermal Delivery: From Hydrogels to Emulsions” 🌿💧
  10. “A Review of the Application of Ganoderma Lucidum (Curtis) P. Karst. in Nanotechnology for the Treatment of Cancer” 🍄💻

Conclusion:

Ana Figueiras’ expertise in pharmaceutical technology, particularly in the development of polymeric micelles for drug delivery, marks her as an outstanding candidate for the Best Researcher Award. She is an exemplary figure in the realm of pharmaceutics with a strong research focus on improving drug therapies for cancer and other severe diseases. Her work continues to advance drug delivery systems, paving the way for future medical breakthroughs. Figueiras demonstrates a strong foundation in academic excellence, research innovation, and collaboration, positioning her as a leader in her field.

Jacob Wekalao | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Mr. Jacob Wekalao | Cancer Cell Biology | Best Researcher Award

Mr. Jacob Wekalao , USTC CHINA , China

Jacob Wekalao is a Physics professional and researcher with extensive experience in both academia and industry. He holds a Doctor of Philosophy from the University of Science and Technology and a Master of Science in Physics from Marwadi University, India. Jacob has worked as a physics teacher, leading the physics department at Kwale High School, Kenya, and is currently a software expert at Eujim Solutions, where he specializes in creating innovative business solutions. He is also a Research Assistant at Marwadi University, contributing to advanced research in physics and nanotechnology. His expertise spans across terahertz sensors, graphene-based biosensors, and surface plasmon resonance techniques. In addition to his academic endeavors, Jacob has authored several peer-reviewed publications, showcasing his contributions to forensic science, health, and biomedical applications. Jacob is passionate about research, mentoring, and leveraging technology to solve real-world problems.

Publication Profile:

Orcid

Strengths for the Award:

Jacob Wekalao is an exceptional researcher in the field of experimental physics, particularly in the areas of nanotechnology, terahertz sensors, and biosensing. His work integrates cutting-edge research with practical applications, demonstrating a high level of innovation and expertise. Jacob’s contributions to the development of graphene-based sensors for various applications, including healthcare, forensic science, and security, have positioned him as a thought leader in his field. His published works in prestigious journals and his active role in research projects, such as designing biosensors for early disease detection, highlight his proficiency in both theoretical and applied physics. Additionally, Jacob’s ability to collaborate internationally and present at major conferences reflects his commitment to advancing scientific knowledge and networking within the global research community.

Areas for Improvement:

While Jacob excels in his research and technological expertise, expanding his focus on interdisciplinary collaborations could further elevate his work. Engaging more with industry experts in areas like artificial intelligence or machine learning could also open doors for more transformative innovations, especially in optimizing sensor technologies. Further involvement in policy or public science initiatives could help bridge the gap between research and broader societal applications.

Education:

Jacob Wekalao has an impressive educational background that supports his expertise in physics and technology. He is currently pursuing a Doctor of Philosophy at the University of Science and Technology, China. His academic journey began with a Bachelor of Education in Science with a focus on Physics and Mathematics from the University of Embu, Kenya (2016-2020). This solid foundation propelled him to obtain a Master of Science in Physics from Marwadi University, Rajkot, Gujarat, India (2021-2023). During his time at Marwadi University, Jacob excelled academically, earning an Academic Gold Medal in November 2023 for his outstanding performance. His commitment to learning is also reflected in certifications from institutions like KAIST and the Israel Institute of Technology. Jacob’s education is characterized by a blend of theoretical knowledge and practical skills, which has enabled him to contribute significantly to the fields of experimental physics and applied technology.

Experience:

Jacob Wekalao has diverse experience spanning education, research, and industry. From September 2019 to August 2021, he worked as a Physics teacher at Kwale High School, Kenya, where he led the physics department, developed curriculum materials, and managed science projects. This role enabled him to foster critical thinking and scientific inquiry among students. In addition to his teaching experience, Jacob is currently employed as a Software Expert at Eujim Solutions, Kenya (July 2023 – Present), where he provides tailored software solutions, improves business efficiency, and implements cutting-edge technologies. Furthermore, he works as a Research Assistant at Marwadi University, collaborating on various physics research projects focused on terahertz sensors and biosensors. His involvement in multiple projects and publications has established him as a valuable contributor to advancements in technology and scientific research. Jacob’s work showcases a seamless integration of theoretical physics and practical application in technology.

Awards and Honors:

Jacob Wekalao’s dedication to academic excellence and research has earned him notable awards and honors. He received the prestigious Academic Gold Medal from Marwadi University, Rajkot, India, in November 2023, recognizing his exceptional performance in the Master of Science in Physics program. Jacob’s achievements are further validated by his numerous peer-reviewed publications, which have contributed to the global scientific community. His research in the fields of biosensing, terahertz technology, and nanomaterials has earned him recognition at various international platforms. In addition to academic awards, Jacob’s work has been presented at leading conferences, such as the International Conference on Chemical Safety and Security for Health and Environment (ICCSSHE), held in India in December 2023. His strong academic performance, leadership in research, and contributions to technological advancements continue to set him apart as an outstanding professional in his field.

Research Focus:

Jacob Wekalao’s research focuses on experimental physics, particularly in the areas of terahertz technology, biosensing, and nanomaterials. His work has significant implications for applications in healthcare, security, and forensic science. Jacob has developed and optimized graphene-based terahertz surface plasmon resonance sensors for the detection of various biomolecules, including hemoglobin and illicit drugs. His research has extended to the design of graphene metasurfaces for efficient detection of diseases like malaria and COVID-19. Jacob’s research in biosensors has led to highly sensitive, cost-effective solutions that hold promise for point-of-care diagnostics and environmental monitoring. Additionally, his work on the use of metasurfaces for explosive detection has practical implications for security. Through his research, Jacob combines advanced theoretical physics with real-world applications, contributing to the fields of biomedical technology, environmental monitoring, and security. His interest in machine learning also aids in optimizing these sensor technologies for better precision and performance.

Publications Top Notes:

  1. “Graphene-based THz surface plasmon resonance biosensor for hemoglobin detection applicable in forensic science.” 📖🔬
  2. “Design of ring and cross-shaped graphene metasurface sensor for efficient detection of malaria and 2-bit encoding applications.” 🦠🔍
  3. “Waterborne bacteria detecting highly sensitive graphene metasurface-based cost-efficient and efficient refractive index sensors.” 💧🔬
  4. “Design of graphene metasurface sensor for efficient detection of COVID-19.” 🦠💡
  5. “Graphene biosensor design based on glass substrate for forensic detection of illicit drugs.” 💊🔍
  6. “Graphene and Gold Metasurface-Based Terahertz Surface Plasmon Resonance Sensor for Explosive Detection.” 💥🛡️
  7. “Terahertz Optical Ultrasensitive Glucose Detection Using Graphene and Silver Surface Plasmon Resonance Metasurfaces for Biomedical Applications.” 🩺🔬
  8. “High-Sensitivity Graphene-Gold Metasurface Optical Biosensor for Early Melanoma Detection Optimized with Machine Learning Using a One-Dimensional Convolutional Neural Network and Binary Encoding.” 🧬🔬

Conclusion:

Jacob Wekalao’s contributions to the fields of physics and technology demonstrate an impressive combination of academic excellence, hands-on expertise, and innovative solutions. His drive to advance scientific knowledge and apply it for real-world impact, especially in healthcare and security, makes him a deserving candidate for the Best Researcher Award. Jacob’s ongoing work on high-sensitivity biosensors and his ability to stay ahead of technological trends make him a standout researcher in his field.

 

 

 

Li Hou | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Li Hou | Cancer Cell Biology | Best Researcher Award

Prof. Li Hou , Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

Li Hou is a distinguished Chief Physician and Director of the Hematology and Oncology Department at Dongzhimen Hospital, affiliated with Beijing University of Chinese Medicine. With a career spanning over 30 years, she has made remarkable contributions in the integration of Traditional Chinese Medicine (TCM) and Western Medicine for treating tumors and blood diseases. A renowned researcher and educator, Hou Li has led over 40 research projects, authored 50+ papers, and published significant work on tumor and blood disease therapies. Her expertise has been recognized with the prestigious “Famous Doctor’s Excellent Demeanor Award” in 2018. Her passion for advancing healthcare through combined approaches has made her a leader in oncology and hematology in China and internationally. 🌟🎓💉

Publication Profile:

Orcid

Strengths for the Award:

Dr. Li Hou is highly deserving of the Best Researcher Award due to her exceptional contributions in integrating Traditional Chinese Medicine (TCM) and Western Medicine for the treatment of hematological diseases and cancers. Her career is distinguished by over 40 research programs and more than 50 published papers, demonstrating her expertise in oncology and hematology. She has authored notable articles in high-impact journals, showcasing her deep understanding of tumor biology and blood disorders. Her leadership in research, coupled with her clinical practice, has led to groundbreaking insights into the treatment of malignancies, including her work on identifying novel drug targets for cancers. Furthermore, her role in academia and professional service, as a key figure in several influential medical associations, highlights her outstanding impact in the medical field. 🌟🧑‍🔬📚

Areas for Improvement:

While Dr. Li Hou research achievements are commendable, expanding her research collaborations internationally could further enhance her impact. Engaging with global research communities may foster new perspectives and facilitate the exchange of ideas, particularly in the context of cutting-edge medical technologies. Additionally, expanding research into the long-term outcomes of integrated therapies in various populations could provide further evidence of the benefits of combining TCM with Western approaches. This would allow her work to gain even more recognition and clinical application worldwide. 🌍🔬

Education:

Li Hou completed her Bachelor’s in Chinese Medicine at Beijing University of Chinese Medicine in 1993. She then pursued her Master’s degree in Integrated Chinese and Western Medicine from the same institution, completing it in 1998. In 2004, she earned her Doctorate in Integrated Chinese and Western Medicine. Her academic journey has been rooted in the application of both traditional and modern methods to treat complex diseases like cancer and blood disorders, providing her with a strong foundation for her career in clinical practice, research, and education. 🎓📚🩺

Experience:

Li Hou clinical career began in 1993 as a resident at Dongzhimen Hospital. By 1999, she advanced to attending physician, and by 2008, she became an associate chief physician. In 2013, she was appointed as Chief Physician at Dongzhimen Hospital, where she has been working ever since. She holds significant leadership roles within the field, including Chairman of several prestigious oncology committees. Additionally, her role as an evaluation expert for the National Natural Science Foundation of China demonstrates her expertise in research. She has been instrumental in combining traditional Chinese medicine with modern treatments in the management of cancer and hematological conditions. 🏥💼👩‍⚕️

Research Focus:

Li Hou research focus revolves around the integration of Traditional Chinese Medicine (TCM) and Western medicine to treat hematological diseases and cancer. She has made significant strides in identifying novel therapeutic approaches, with an emphasis on improving cancer treatment outcomes. Her work includes studying the role of TCM in modulating drug responses and enhancing chemotherapy effectiveness. Through her extensive research, she has contributed to understanding the genetic and molecular mechanisms involved in blood cancer and tumor progression, aiming to optimize patient care and survival rates. Her studies have been published in leading medical journals. 🧬🔬💡

Publications Top Notes:

  • Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome – Journal of Pharmaceutical and Biomedical Analysis (2025)
  • Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia – Computers in Biology and Medicine (2024)
  • Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study – Cancer Medicine (2023)
  • Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis – Clinical Lymphoma Myeloma and Leukemia (2023)
  • Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells – Evidence-Based Complementary and Alternative Medicine (2021)
  • Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial – Pain Research and Management (2020) 📝📚🎯

Conclusion:

Dr. Li Hou contributions to medicine are profound and multifaceted, blending traditional and modern therapeutic approaches to offer innovative solutions for cancer and blood diseases. Her research has not only advanced scientific knowledge but also improved patient care. As a leader in both clinical practice and research, she exemplifies the qualities of a Best Researcher Award recipient. Through her continued dedication to her work, Dr. Hou Li will undoubtedly remain at the forefront of medical research, driving progress in both China and globally. 🏆💉🩺

 

 

 

 

Iwona Kwiecień | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Iwona Kwiecień | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Iwona Kwiecień , Military Institute of Medicine – National Research Institute , Poland

Iwona Kwiecień, PhD, is an expert in clinical immunology and laboratory medicine. With a strong academic background and extensive experience in medical research, she has dedicated her career to exploring immunological mechanisms in various diseases. She is currently working at the Military Institute of Medicine in Warsaw, where she serves as a lab specialist and lecturer. Dr. Kwiecień holds a PhD in Medical Science with a specialization in immunology from the Medical University of Warsaw. Her research focuses on the immune response in lung cancer, sarcoidosis, and other inflammatory diseases, employing advanced techniques such as multicolor flow cytometry. Her scientific contributions have been recognized globally, and she continues to shape the field of immunology through her research and teaching.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Iwona Kwiecień possesses an impressive academic background and a consistent record of significant contributions to the field of immunology and medical research. With a Ph.D. in Medical Science and immunology, along with expertise in laboratory medicine, hematology, and flow cytometry, Dr. Kwiecień has shown remarkable skill in investigating the immune system’s role in lung cancer and other diseases. Her work on antigenic profiles in the lung cancer microenvironment, macrophage subpopulations in lung cancer, and immune responses in systemic inflammation highlights her strong research abilities. The 2024 habilitation diploma is a testament to her research excellence. Furthermore, Dr. Kwiecień has contributed to the publication of numerous peer-reviewed articles with significant citations and impact, indicating her strong presence in the scientific community.

Areas for Improvement:

While Dr. Kwiecień has demonstrated significant strength in immunological research, expanding her focus to include other cancer types or diseases beyond lung cancer may broaden the scope of her impact. Additionally, fostering greater international collaboration could further enhance the dissemination of her research globally.

Education:

Iwona Kwiecień earned her Master of Science in Laboratory Medicine from the Medical University of Warsaw in 2012. Later, she completed her PhD at the same university’s First Faculty of Medicine, specializing in immunology, with a thesis on regulatory mechanisms of the immune response, which she defended in 2017. She further pursued a specialization in Laboratory Medical Hematology at the Medical University of Silesia in Katowice, Poland, completing it in 2021. Dr. Kwiecień is also set to receive her habilitation diploma from the Military Institute of Medicine-National Research Institute in 2024, based on her scientific achievements in lung cancer immunology. Throughout her academic journey, she has developed expertise in clinical cytology, flow cytometry, and immunological assays, contributing significantly to the scientific community.

Experience:

Dr. Iwona Kwiecień has accumulated substantial experience in the field of laboratory medicine and immunology, working at several prestigious institutions. Since 2017, she has been a laboratory specialist and lecturer at the Military Institute of Medicine-National Research Institute in Warsaw, focusing on flow cytometry and hematology. Her role involves designing, performing, and analyzing complex experiments, as well as providing education and training to students. Prior to her current position, Dr. Kwiecień worked as a research coordinator assistant at BioVirtus Research Site and Clinical Research Group in Warsaw. Her academic career also includes time spent at the University Clinical Center of the Medical University of Warsaw, where she collaborated on various pathology and immunology projects. Dr. Kwiecień’s professional experience extends to overseeing numerous grants and research projects, including her work on macrophage subpopulations and lung cancer.

Awards and Honors:

Dr. Iwona Kwiecień has received several accolades in recognition of her outstanding contributions to science and research. Among her awards is the prestigious “Gold Laurel Graduate” medal for being the best graduate of Laboratory Medicine at the Medical University of Warsaw in 2013. She also received the 2nd award from the Polish Archives of Internal Medicine for her student research on macrophage subpopulations in sarcoidosis in 2014. Additionally, Dr. Kwiecień has been the recipient of numerous research grants, including the 2014-2015 Grant for Young Scientific Researcher from the Medical University of Warsaw. Her work on macrophage subpopulations in lung cancer earned her a statutory grant at the Military Institute of Medicine in 2018-2019. These awards reflect her exceptional research contributions and commitment to advancing the field of clinical immunology and laboratory medicine.

Research Focus:

Dr. Iwona Kwiecień’s research focus lies primarily in the immunology of lung cancer, sarcoidosis, and inflammatory diseases. Her studies have explored immune responses, particularly the role of macrophages, regulatory T cells, and other immune cell populations in disease progression. A key area of her research involves the use of multicolor flow cytometry to assess antigenic profiles of cells in cancer microenvironments. She has contributed to the understanding of how immune cells, such as T cells and macrophages, interact with tumor cells in the context of lung cancer and other inflammatory conditions. Dr. Kwiecień has also researched the impact of systemic inflammation on diseases like obstructive sleep apnea. Her work aims to uncover novel therapeutic targets and provide insights into the immune mechanisms driving various pathologies. Through her research, Dr. Kwiecień continues to contribute valuable knowledge to the fields of clinical immunology and hematology.

Publications Top Notes:

  1. Frequency and spontaneous cytotoxicity of natural killer cells in healthy children: preliminary results 🧬🧒
  2. Association between M1 and M2 macrophages in bronchoalveolar lavage fluid and tobacco smoking in patients with sarcoidosis 💨🫁
  3. Cytometric analysis of perforin expression in NK cells, CD8+, and CD4+ lymphocytes in children with autoimmune Hashimoto’s thyroiditis 👶🦠
  4. T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnea 😴🩺
  5. Macrophage polarization in interstitial lung diseases 💔🫁
  6. D4+/CD25high/FoxP3+/CD127- regulatory T cells in bronchoalveolar lavage fluid of lung cancer patients 🫀💉
  7. Elevated regulatory T cells, surface and intracellular CTLA‐4 expression and interleukin‐17 in the lung cancer microenvironment in humans 🫀🧪
  8. Elevated Foxp3/CD8 ratio in lung adenocarcinoma metastatic lymph nodes resected by transcervical extended mediastinal lymphadenectomy 🔬💊
  9. Immunophenotype of t cells expressing programmed death-1 and cytotoxic T cell antigen-4 in early lung cancer: local vs. systemic immune response 🎗️🫁
  10. Fas-positive lymphocytes are associated with systemic inflammation in obstructive sleep Apnea syndrome 🛏️🔬

Conclusion:

Dr. Iwona Kwiecień is a highly capable researcher whose work has made substantial contributions to clinical immunology. Her ongoing focus on the immune responses in cancer offers significant potential for advancing cancer diagnostics and therapeutics. With a strong academic and research background, she is undoubtedly a strong candidate for the Best Researcher Award.